Systemic injection of anti-CD40 can produce detrimental side effects in cancer patients and liposome based delivery of anti-CD40 to the TDLN has been shown to reduce harmful side effects often observed in systemic treatment [169]. This evidence concerns the gene CD40 and cancer.